Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-05-31
2011-05-31
Li, Q. Janice (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S300000, C514S04400A
Reexamination Certificate
active
07951925
ABSTRACT:
Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
REFERENCES:
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5356802 (1994-10-01), Chandrasegaran
patent: 5420032 (1995-05-01), Marshall
patent: 5422251 (1995-06-01), Fresco
patent: 5436150 (1995-07-01), Chandrasegaran
patent: 5487994 (1996-01-01), Chandrasegaran
patent: 5585245 (1996-12-01), Nils et al.
patent: 5789538 (1998-08-01), Rebar et al.
patent: 5925523 (1999-07-01), Dove et al.
patent: 6007988 (1999-12-01), Choo et al.
patent: 6013453 (2000-01-01), Choo et al.
patent: 6140081 (2000-10-01), Barbas
patent: 6140466 (2000-10-01), Barbas et al.
patent: 6200759 (2001-03-01), Dove et al.
patent: 6242568 (2001-06-01), Barbas et al.
patent: 6453242 (2002-09-01), Eisenberg et al.
patent: 6503717 (2003-01-01), Case et al.
patent: 6534261 (2003-03-01), Cox et al.
patent: 6599692 (2003-07-01), Case et al.
patent: 6607882 (2003-08-01), Cox, III et al.
patent: 6689558 (2004-02-01), Case
patent: 6787316 (2004-09-01), Stewart et al.
patent: 6824978 (2004-11-01), Cox, III et al.
patent: 6833252 (2004-12-01), Dujon et al.
patent: 6933113 (2005-08-01), Case et al.
patent: 6979539 (2005-12-01), Cox, III et al.
patent: 7013219 (2006-03-01), Case et al.
patent: 7163824 (2007-01-01), Cox, III et al.
patent: 2003/0232410 (2003-12-01), Liljedahl et al.
patent: 2003/0233672 (2003-12-01), Li et al.
patent: 2005/0026157 (2005-02-01), Baltimore
patent: 2005/0064474 (2005-03-01), Urnov et al.
patent: 2005/0208489 (2005-09-01), Carroll
patent: 2006/0188987 (2006-08-01), Guschan et al.
patent: 2007/0134796 (2007-06-01), Holmes et al.
patent: 2338237 (1999-12-01), None
patent: WO 95/19431 (1995-07-01), None
patent: WO 96/06166 (1996-02-01), None
patent: WO 98/37186 (1998-08-01), None
patent: WO 98/44350 (1998-10-01), None
patent: WO 98/53057 (1998-11-01), None
patent: WO 98/53058 (1998-11-01), None
patent: WO 98/53059 (1998-11-01), None
patent: WO 98/53060 (1998-11-01), None
patent: WO 98/54311 (1998-12-01), None
patent: WO 00/27878 (2000-05-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/88197 (2001-11-01), None
patent: WO 02/16536 (2002-02-01), None
patent: WO 02/057308 (2002-07-01), None
patent: WO 02/099084 (2002-12-01), None
patent: WO 03/016496 (2003-02-01), None
patent: WO 2007/014275 (2007-01-01), None
Dean et al. Science 1996;273:1856-62.
Jemieson et al. Nat Rev 2003;2:361-8.
Perez et al, Nat Biotechnol 2008;26:808-16.
Alkhatib, “CC CKR5: A Rantes, MIP-1{acute over (α)}, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1,”Science272:1955-1958 (1996).
Alvarez, et al. “A Phase I Study of Recombinant Adenovirus Vector-Mediated Intraperitoneal Delivery of Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene and Intravenous Ganciclovir for Previously Treated Ovarian and Extraovarian Cancer Patients,”Hum. Gene Ther. 8(5):597-613 (1997).
Argast, et al., “I-PPOI and I-CREI Homing Site Sequence Degeneracy Determined by Random Mutagenesis and Sequential In Vitro Enrichment,”J. Mol. Biol. 280:345-353 (1998).
Ashworth, et al., “Computational Redesign of Endonuclease DNA Binding and Cleavage Specificity,”Nature441:656-659 (2006).
Beerli, et al., “Engineering Polydactyl Zinc-Finger Transcription Factors,”Nature Biotechnology20:135-141 (2002).
Berger, et al., “Chemokine Receptors as HIV-1 Coreceptors: Roles in Viral Entry, Tropism, and Disease,”Annu Rev Immunology17:657-700 (1999).
Belfort, et al., “Homing Endonucleases: Keeping the House in Order,”Nucleic Acids Research25:3379-3388 (1997).
Bitinate, et al., “FOKI Dimerization is Required for DNA Cleavage,”PNAS USA95:10570-10575 (1998).
Chevalier, et al., “Design, Activity, and Structure of a Highly Specific Artificial Endonuclease,”Molecular Cell10:895-905 (2002).
Choo, et al., “Advances in Zinc Finger Engineering,”Curr. Opin. Struct. Biol. 10:411-416 (2000).
Deng, et al., “Identification of a Major Co-Receptor for Primary Isolates of HIV-1,”Nature381:661-666 (1996).
Dujon, et al., “Mobile Introns: Definition of Terms and Recommended Nomenclature,”Gene82:115-118 (1989).
Epinat, et al., “A Novel Engineered Meganuclease Induces Homologous Recombination in Yeast and Mammalian Cells,”Nucleic Acids Research31:2952-2962 (2003).
Fätkenheuer, et al., “Efficacy of Short-Term Monotherapy With Maraviroc, a New CCRS Antagonist, in Patients Infected With HIV-1,”Nat Med11:1170-1172 (2005).
Fields, et al., “A Novel Genetic System to Detect Protein-Protein Interactions,”Nature340:245-246 (1989).
Gimble, et al., “Substrate Recognition and Induced DNA Distortion by the PI-SCEI Endonuclease, an Enzyme Generated by Protein Splicing,”J. Mol. Biol. 263:163-180 (1996).
Gribskov, et al., “Sigma Factors FromE. coli, B. subtilis, Phage SP01 , and Phage T4 are Homologous Proteins,”Nucl Acids Res. 14(6):6745-6763 (1986).
Huang, et al., “The Role of a Mutant CCR5 Allele in HIV-1 Transmission and Disease Progression,”Nat Med2:1240-1243 (1996).
Hung, et al., “Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 GP120 Involved in CCR5 Utilization,”J. Virology73:8216-8226 (1999).
Isalan et al., “A Rapid, Generally Applicable Method to Engineer Zinc Fingers Illustrated by Targeting the HIV-1 Promoter,”Nat Biotechnol19:656-660 (2001).
Jasin, et al., “Genetic Manipulation of Genomes With Rare-Cutting Endonucleases,”Trends Genet12:224-228 (1996).
Kim, et al., “Insertion and Deletion Mutants of FOKI Restriction Endonuclease,”J. Biol. Chem. 269:31978-31981 (1994).
Kim, et al., “Chimeric Restriction Endonuclease,”PNAS USA91:883-887 (1994).
Kuhmann, et al., “Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type I Escape from a Small-Molecule CCR5 Inhibitor,”J. Virol78:2790-2807 (2004).
Levine, et al., “Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T Cells in the Absence of Exogenous Feeder Cells,”J. Immunology159:5921-5930 (1997).
Levine, et al., “Gene Transfer in Humans Using a Conditionally Replicating Lentiviral Vector,”PNAS USA103:17372-17377 (2006).
Li, et al., “Functional Domains in FOK I Restriction Endonuclease,”PNAS USA89:4275-4279 (1992).
Li, et al., “Alteration of the Cleavage Distance of FOK I Restriction Endonuclease by Insertion Mutagenesis,”PNAS USA90:2764-2768 (1993).
Liu, et al., “Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection,”Cell86:367-377 (1996).
Morner, et al., “Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage,”J. Virology73:2343-2349 (1999).
Ni, et al., “Evaluation of Biodistribution and Safety of Adenovirus Vectors Containing Group B Fibers After Intravenous Injection Into Baboons,”Hum Gene Ther16:664-677 (2005).
Nilsson, et al., “Functionally Distinct Subpopulations of Cord Blood CD34+ Cells are Transduced by Adenoviral Vectors With Serotype 5 or 35 Tropism,”Mol Ther9:377-388 (2004).
Nilsson, et al., “Development of an Adenoviral Vector System With Adenovirus Serotype 35 Tropism; Efficient Transient Gene Transfer Into Primary Malignant Hematopoietic Cells,”J Gene Med6:631-641 (2004).
Oleykowski, et al., “Mutation Detection Using a Novel Plant Endonuclease,”Nucleic Acids Research26:4597-4602 (1998).
Pabo, et al., “Design and S
Ando Dale
Holmes Michael C.
Lee Gary Ka Leong
Li Q. Janice
Pasternak Dahna S.
Robins & Pasternak LLP
Sangamo Biosciences, Inc.
LandOfFree
Methods and compositions for gene inactivation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for gene inactivation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for gene inactivation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706146